264 related articles for article (PubMed ID: 19653866)
1. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Thorén FB; Romero AI; Brune M; Hellstrand K
Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
[TBL] [Abstract][Full Text] [Related]
3. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
Romero AI; Thorén FB; Aurelius J; Askarieh G; Brune M; Hellstrand K
Scand J Immunol; 2009 Sep; 70(3):194-205. PubMed ID: 19703009
[TBL] [Abstract][Full Text] [Related]
4. Histamine dihydrochloride: in the management of acute myeloid leukaemia.
Yang LP; Perry CM
Drugs; 2011 Jan; 71(1):109-22. PubMed ID: 21175244
[TBL] [Abstract][Full Text] [Related]
5. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
[TBL] [Abstract][Full Text] [Related]
6. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
7. Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.
Sander FE; Nilsson M; Rydström A; Aurelius J; Riise RE; Movitz C; Bernson E; Kiffin R; Ståhlberg A; Brune M; Foà R; Hellstrand K; Thorén FB; Martner A
Cancer Immunol Immunother; 2017 Nov; 66(11):1473-1484. PubMed ID: 28721449
[TBL] [Abstract][Full Text] [Related]
8. Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia--background and results.
Brune M; Romero AI; Hellstrand K
Inflamm Res; 2009 Apr; 58 Suppl 1():4-8. PubMed ID: 19271134
[No Abstract] [Full Text] [Related]
9. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
[TBL] [Abstract][Full Text] [Related]
10. Histamine and interleukin-2 in acute myelogenous leukemia.
Hellstrand K; Mellqvist UH; Wallhult E; Carneskog J; Kimby E; Celsing F; Brune M
Leuk Lymphoma; 1997 Nov; 27(5-6):429-38. PubMed ID: 9477124
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.
Sander FE; Rydström A; Bernson E; Kiffin R; Riise R; Aurelius J; Anderson H; Brune M; Foà R; Hellstrand K; Thorén FB; Martner A
Oncotarget; 2016 Feb; 7(7):7586-96. PubMed ID: 26863635
[TBL] [Abstract][Full Text] [Related]
12. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
Brune M; Castaigne S; Catalano J; Gehlsen K; Ho AD; Hofmann WK; Hogge DE; Nilsson B; Or R; Romero AI; Rowe JM; Simonsson B; Spearing R; Stadtmauer EA; Szer J; Wallhult E; Hellstrand K
Blood; 2006 Jul; 108(1):88-96. PubMed ID: 16556892
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia.
Bernson E; Hallner A; Sander FE; Nicklasson M; Nilsson MS; Christenson K; Aydin E; Liljeqvist JÅ; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Cancer Immunol Res; 2018 Sep; 6(9):1110-1119. PubMed ID: 29980537
[TBL] [Abstract][Full Text] [Related]
14. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia.
Brune M; Hellstrand K
Br J Haematol; 1996 Mar; 92(3):620-6. PubMed ID: 8616026
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.
Rydström A; Hallner A; Aurelius J; Sander FE; Bernson E; Kiffin R; Thoren FB; Hellstrand K; Martner A
J Leukoc Biol; 2017 Aug; 102(2):467-474. PubMed ID: 28235771
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.
Nilsson MS; Hallner A; Brune M; Nilsson S; Thorén FB; Martner A; Hellstrand K
Hum Vaccin Immunother; 2020; 16(1):109-111. PubMed ID: 31242079
[TBL] [Abstract][Full Text] [Related]
17. Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation.
Cuapio A; Post M; Cerny-Reiterer S; Gleixner KV; Stefanzl G; Basilio J; Herndlhofer S; Sperr WR; Brons NH; Casanova E; Zimmer J; Valent P; Hofer E
Oncotarget; 2016 Jul; 7(29):46466-46481. PubMed ID: 27341131
[TBL] [Abstract][Full Text] [Related]
18. Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15.
Blaser BW; Caligiuri MA
Best Pract Res Clin Haematol; 2006; 19(2):281-92. PubMed ID: 16516125
[TBL] [Abstract][Full Text] [Related]
19. Natural killer activity in patients with acute myelocytic leukemia.
Stupp Y; Rosenkovitch E; Izak G
Isr J Med Sci; 1978 Dec; 14(12):1212-5. PubMed ID: 311767
[TBL] [Abstract][Full Text] [Related]
20. Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance.
Grauers Wiktorin H; Aydin E; Christenson K; Issdisai N; Thorén FB; Hellstrand K; Martner A
Oncoimmunology; 2021; 10(1):1944538. PubMed ID: 34367728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
